GENE ONLINE|News &
Regulatory
Johnson & Johnson Under Fire Again as Legal Action Over Alleged Talc-Cancer Link Moves to the UK
2025-02-05
Key Tech and Workforce Highlights in the U.S. 2025 Intel Authorization Bill—An NDAA Pillar
2024-12-26
Eli Lilly’s Zepbound Becomes First and Only FDA Approved Weight Loss Drug to Treat Obstructive Sleep Apnea
2024-12-23
BIOSECURE Act Absent in Key U.S. Defense Bill—Slim Chance of Passing December 20 Resolution
2024-12-20
Eli Lilly’s Alzheimer’s Treatment Kisunla Secures Fourth Major Market Approval with NMPA Authorization in China
2024-12-18
Opening the Door to ‘Designer Babies’? South Africa’s Genome Editing Guidelines Spark Global Debate
2024-11-08
FDA to Reassess Shortage Status of Key Obesity Drugs; Compounding Stocks Out of the Red—for Now
2024-10-16
Biogen and UCB Promising Phase-III Trial Data for Lupus; CAR T-Cell Therapy Another Autoimmune Treatment Avenue
2024-09-25
Illumina’s IVD Biomarker Test Becomes the First FDA-approved Pan-cancer Companion Diagnostics Kit
2024-09-11
LATEST
Psychedelics Inching Forward – Psilocybin Therapy Shows Sustained Benefits for Treatment-Resistant Depression
2025-03-24
Healthcare Through the Eyes of AI: Coding the Future of Medicine Through Digital Acceleration
2025-03-21
European Pharmaceutical Review Highlights RNA Therapeutics and Process Analytical Technology in 2025 Issue 1
2025-03-21
